Several biomarkers may also predict the efficacy of ICIs, such as PD-L1 expression, the number of TIL, number of CD4+ T cells, tumor mutational burden (TMB) status, microsatellite instability (MSI) status, mismatch-repair deficiency (dMMR), age, etc. [106]. This evidence concerns the gene CD274 and neoplasm.